Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 05, 2024 19:10 ET | Source: Belite Bio, Inc

Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results

SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
July 08, 2024 08:00 ET | Source: Belite Bio, Inc

Belite Bio to Present at the JonesHealthcare Seaside Summit

SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
June 12, 2024 02:55 ET | Source: Belite Bio, Inc

Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan

Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related...
May 14, 2024 08:00 ET | Source: Belite Bio, Inc

Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference

SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
May 13, 2024 21:50 ET | Source: Belite Bio, Inc

Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update

Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related...
May 13, 2024 08:00 ET | Source: Belite Bio, Inc

Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
May 08, 2024 08:00 ET | Source: Belite Bio, Inc

Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative...
May 06, 2024 08:15 ET | Source: Belite Bio, Inc

Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant

Webinar, moderated by Cantor Fitzgerald, will be held on Monday, May 13, 2024, at 2:00 p.m. ET Discussion will feature Dr. Michel Michaelides, leading expert in the field of inherited eye disease...
May 06, 2024 08:00 ET | Source: Belite Bio, Inc

Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting

Additional analysis of visual acuity loss, genotypic profiles, and retinal imaging data from a 24-month Phase 2 trial of Tinlarebant in adolescent Stargardt disease patients provides further support...
May 01, 2024 16:15 ET | Source: Belite Bio, Inc

Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related...